No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

EyeOn LifeLine Is a Potentially Life-Saving Eye Tracking Communication Tablet for Hospital ERs and ICUs

Editor: What To Know

  • EyeTech Digital Systems has launched FDA-registered EyeOn LifeLine, a potentially life-saving eye-tracking communication tablet for hospital ERs and ICUs, so doctors, nurses and caregivers can easily and quickly communicate with their critical COVID-19 patients, who are unable to speak while confined to their hospital beds.
  • The stand-mounted tablet faces the patient who simply looks at word squares to express pain level or a request, and the tablet voices it through speakers for nurses and doctors.
  • But the entire team jumped into action to modify the software and firmware to create EyeOn LifeLine, so COVID-19 patients can communicate critical needs to their healthcare workers while intubated or using a ventilator or respirator.

EyeTech Digital Systems has launched FDA-registered EyeOn LifeLine, a potentially life-saving eye-tracking communication tablet for hospital ERs and ICUs, so doctors, nurses and caregivers can easily and quickly communicate with their critical COVID-19 patients, who are unable to speak while confined to their hospital beds.

The stand-mounted tablet faces the patient who simply looks at word squares to express pain level or a request, and the tablet voices it through speakers for nurses and doctors.

EyeOn LifeLine is ultra-portable so it can be utilized with multiple patients during this pandemic, to improve patient outcomes.

EyeTech launched the EyeOn self-calibrating augmented and alternative communication (AAC) device earlier this year for people with ALS, cerebral palsy, muscular dystrophy, spinal cord injuries, Rett Syndrome, traumatic brain injuries or stroke as well as those on the autism spectrum. But the entire team jumped into action to modify the software and firmware to create EyeOn LifeLine, so COVID-19 patients can communicate critical needs to their healthcare workers while intubated or using a ventilator or respirator.

“As a long-time eye-gaze user with hand disabilities, I was devastated to see doctors and nurses not being able to communicate with ICU patients under a ventilator,” EyeTech CEO Robert Chappell said. “If we can save one life, it will be a huge contribution. I just wish we had enough units to serve all the ICUs around the country. Chappell concluded, “We are also donating $500 per unit to the American Nurses Foundation to express our heartfelt support to those fighting this pandemic on the frontlines.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy